Met Life Investment Management, LLC Provention Bio, Inc. Transaction History

Met Life Investment Management, LLC

  • $16.6 Billion
  • Q2 2024

Shares

37 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2024
BUY
$6.7 - $24.21 $222,105 - $802,561
33,150 New
33,150 $799 Million
Q1 2023

May 15, 2023
BUY
$6.7 - $24.21 $15,852 - $57,280
2,366 Added 7.69%
33,150 $798,000
Q4 2022

Jun 14, 2023
SELL
$4.52 - $10.57 $10,694 - $25,008
-2,366 Reduced 7.14%
30,784 $325,000
Q3 2022

May 10, 2024
BUY
$3.43 - $5.62 $75,034 - $122,943
21,876 Added 245.58%
30,784 $138,000
Q3 2022

Jun 14, 2023
SELL
$3.43 - $5.62 $8,115 - $13,296
-2,366 Reduced 7.14%
30,784 $138,000
Q3 2022

Mar 22, 2023
BUY
$3.43 - $5.62 $75,034 - $122,943
21,876 Added 245.58%
30,784 $138,000
Q3 2022

Nov 14, 2022
BUY
$3.43 - $5.62 $75,034 - $122,943
21,876 Added 245.58%
30,784 $139,000
Q2 2022

May 10, 2024
SELL
$3.65 - $7.3 $85,804 - $171,608
-23,508 Reduced 72.52%
8,908 $35,000
Q2 2022

Jun 20, 2023
SELL
$3.65 - $7.3 $88,483 - $176,966
-24,242 Reduced 73.13%
8,908 $35,000
Q2 2022

Mar 22, 2023
SELL
$3.65 - $7.3 $85,804 - $171,608
-23,508 Reduced 72.52%
8,908 $35,000
Q2 2022

Aug 11, 2022
SELL
$3.65 - $7.3 $85,804 - $171,608
-23,508 Reduced 72.52%
8,908 $36,000
Q1 2022

May 10, 2024
BUY
$3.4 - $7.88 $110,214 - $255,438
32,416 New
32,416 $237,000
Q1 2022

Jun 20, 2023
SELL
$3.4 - $7.88 $2,495 - $5,783
-734 Reduced 2.21%
32,416 $237,000
Q1 2022

Mar 22, 2023
BUY
$3.4 - $7.88 $85,010 - $197,023
25,003 Added 337.29%
32,416 $237,000
Q1 2022

May 12, 2022
BUY
$3.4 - $7.88 $85,010 - $197,023
25,003 Added 337.29%
32,416 $237,000
Q4 2021

May 17, 2024
SELL
$5.59 - $7.39 $74,190 - $98,080
-13,272 Reduced 64.16%
7,413 $41,000
Q4 2021

Jun 21, 2023
SELL
$5.59 - $7.39 $143,869 - $190,196
-25,737 Reduced 77.64%
7,413 $41,000
Q4 2021

Mar 22, 2023
SELL
$5.59 - $7.39 $74,190 - $98,080
-13,272 Reduced 64.16%
7,413 $41,000
Q4 2021

Feb 15, 2022
SELL
$5.59 - $7.39 $74,190 - $98,080
-13,272 Reduced 64.16%
7,413 $42,000
Q3 2021

May 17, 2024
BUY
$5.66 - $8.33 $71,236 - $104,841
12,586 Added 155.4%
20,685 $132,000
Q3 2021

Jun 21, 2023
SELL
$5.66 - $8.33 $70,551 - $103,833
-12,465 Reduced 37.6%
20,685 $132,000
Q3 2021

Mar 22, 2023
BUY
$5.66 - $8.33 $71,236 - $104,841
12,586 Added 155.4%
20,685 $132,000
Q3 2021

Nov 15, 2021
BUY
$5.66 - $8.33 $71,236 - $104,841
12,586 Added 155.4%
20,685 $132,000
Q2 2021

May 17, 2024
SELL
$6.71 - $11.04 $90,564 - $149,006
-13,497 Reduced 62.5%
8,099 $68,000
Q2 2021

Jun 21, 2023
SELL
$6.71 - $11.04 $168,092 - $276,563
-25,051 Reduced 75.57%
8,099 $68,000
Q2 2021

Mar 22, 2023
SELL
$6.71 - $11.04 $90,564 - $149,006
-13,497 Reduced 62.5%
8,099 $68,000
Q2 2021

Aug 16, 2021
SELL
$6.71 - $11.04 $90,564 - $149,006
-13,497 Reduced 62.5%
8,099 $68,000
Q1 2021

May 17, 2024
BUY
$10.12 - $19.45 $218,551 - $420,042
21,596 New
21,596 $226,000
Q1 2021

Jun 26, 2023
SELL
$10.12 - $19.45 $116,926 - $224,725
-11,554 Reduced 34.85%
21,596 $227 Million
Q1 2021

Mar 22, 2023
BUY
$10.12 - $19.45 $19,926 - $38,297
1,969 Added 10.03%
21,596 $226,000
Q1 2021

May 14, 2021
BUY
$10.12 - $19.45 $19,926 - $38,297
1,969 Added 10.03%
21,596 $227,000
Q4 2020

Jun 22, 2023
SELL
$11.79 - $18.94 $159,436 - $256,125
-13,523 Reduced 40.79%
19,627 $332,000
Q3 2020

Jun 26, 2023
SELL
$10.34 - $15.2 $139,827 - $205,549
-13,523 Reduced 40.79%
19,627 $251,000
Q2 2020

May 24, 2024
BUY
$7.81 - $17.0 $153,286 - $333,659
19,627 New
19,627 $277 Million
Q2 2020

Jun 26, 2023
SELL
$7.81 - $17.0 $105,614 - $229,891
-13,523 Reduced 40.79%
19,627 $276,000
Q2 2020

Mar 22, 2023
SELL
$7.81 - $17.0 $87,136 - $189,669
-11,157 Reduced 36.24%
19,627 $276,000
Q2 2020

Aug 14, 2020
BUY
$7.81 - $17.0 $153,286 - $333,659
19,627 New
19,627 $277,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0
View Full List

About Provention Bio, Inc.

PRVB Quotes by TradingView
  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email